Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
Despite the durable remissions induced by ICIs and targeted therapies in advanced melanoma and non-melanoma skin cancers, both subtypes usually relapse. Many systematic therapies have been tested to increase efficacy and delay relapse in ICIs, but their success has been limited. Due the feasibility...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/12/2873 |
| _version_ | 1797489202556829696 |
|---|---|
| author | Dimitrios C. Ziogas Anastasios Martinos Dioni-Pinelopi Petsiou Amalia Anastasopoulou Helen Gogas |
| author_facet | Dimitrios C. Ziogas Anastasios Martinos Dioni-Pinelopi Petsiou Amalia Anastasopoulou Helen Gogas |
| author_sort | Dimitrios C. Ziogas |
| collection | DOAJ |
| description | Despite the durable remissions induced by ICIs and targeted therapies in advanced melanoma and non-melanoma skin cancers, both subtypes usually relapse. Many systematic therapies have been tested to increase efficacy and delay relapse in ICIs, but their success has been limited. Due the feasibility of this approach, skin cancers have become the ideal platform for intralesional infusions of many novel agents, including oncolytic viruses (OVs). Talimogene laherparepvec (T-VEC) was the first FDA-approved OV for the treatment of unresectable melanoma and this virus opened up further potential for the use of this class of agents, especially in combination with ICIs, in order to achieve deeper and longer immune-mediated responses. However, the recently announced phase III MASTERKEY-265 trial was not able to confirm that the addition of T-VEC to pembrolizumab treatment improves progression-free or overall survival over the use of pembrolizumab alone. Despite these results, numerous studies are currently active, evaluating T-VEC and several other OVs as monotherapies or in regimens with ICIs in different subtypes of skin cancer. This overview provides a comprehensive update on the evolution status of all available OVs in melanoma and non-melanoma skin cancers and summarizes the more interesting preclinical findings, the latest clinical evidence, and the future insights in relation to the expected selective incorporation of some of these OVs into oncological practice. |
| first_indexed | 2024-03-10T00:13:09Z |
| format | Article |
| id | doaj.art-79062c2d3d8046fda9f211b623b4c8f6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:13:09Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-79062c2d3d8046fda9f211b623b4c8f62023-11-23T15:55:39ZengMDPI AGCancers2072-66942022-06-011412287310.3390/cancers14122873Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin CancersDimitrios C. Ziogas0Anastasios Martinos1Dioni-Pinelopi Petsiou2Amalia Anastasopoulou3Helen Gogas4First Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, GreeceDespite the durable remissions induced by ICIs and targeted therapies in advanced melanoma and non-melanoma skin cancers, both subtypes usually relapse. Many systematic therapies have been tested to increase efficacy and delay relapse in ICIs, but their success has been limited. Due the feasibility of this approach, skin cancers have become the ideal platform for intralesional infusions of many novel agents, including oncolytic viruses (OVs). Talimogene laherparepvec (T-VEC) was the first FDA-approved OV for the treatment of unresectable melanoma and this virus opened up further potential for the use of this class of agents, especially in combination with ICIs, in order to achieve deeper and longer immune-mediated responses. However, the recently announced phase III MASTERKEY-265 trial was not able to confirm that the addition of T-VEC to pembrolizumab treatment improves progression-free or overall survival over the use of pembrolizumab alone. Despite these results, numerous studies are currently active, evaluating T-VEC and several other OVs as monotherapies or in regimens with ICIs in different subtypes of skin cancer. This overview provides a comprehensive update on the evolution status of all available OVs in melanoma and non-melanoma skin cancers and summarizes the more interesting preclinical findings, the latest clinical evidence, and the future insights in relation to the expected selective incorporation of some of these OVs into oncological practice.https://www.mdpi.com/2072-6694/14/12/2873oncolytic virusesimmunotherapyskin cancermelanomatalimogene laherparepvec (T-VEC) |
| spellingShingle | Dimitrios C. Ziogas Anastasios Martinos Dioni-Pinelopi Petsiou Amalia Anastasopoulou Helen Gogas Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers Cancers oncolytic viruses immunotherapy skin cancer melanoma talimogene laherparepvec (T-VEC) |
| title | Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers |
| title_full | Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers |
| title_fullStr | Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers |
| title_full_unstemmed | Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers |
| title_short | Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers |
| title_sort | beyond immunotherapy seizing the momentum of oncolytic viruses in the ideal platform of skin cancers |
| topic | oncolytic viruses immunotherapy skin cancer melanoma talimogene laherparepvec (T-VEC) |
| url | https://www.mdpi.com/2072-6694/14/12/2873 |
| work_keys_str_mv | AT dimitrioscziogas beyondimmunotherapyseizingthemomentumofoncolyticvirusesintheidealplatformofskincancers AT anastasiosmartinos beyondimmunotherapyseizingthemomentumofoncolyticvirusesintheidealplatformofskincancers AT dionipinelopipetsiou beyondimmunotherapyseizingthemomentumofoncolyticvirusesintheidealplatformofskincancers AT amaliaanastasopoulou beyondimmunotherapyseizingthemomentumofoncolyticvirusesintheidealplatformofskincancers AT helengogas beyondimmunotherapyseizingthemomentumofoncolyticvirusesintheidealplatformofskincancers |